PT3789389T - Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida - Google Patents
Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamidaInfo
- Publication number
- PT3789389T PT3789389T PT197971435T PT19797143T PT3789389T PT 3789389 T PT3789389 T PT 3789389T PT 197971435 T PT197971435 T PT 197971435T PT 19797143 T PT19797143 T PT 19797143T PT 3789389 T PT3789389 T PT 3789389T
- Authority
- PT
- Portugal
- Prior art keywords
- crystal form
- thiophene derivative
- thiophene
- derivative
- crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810407741 | 2018-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3789389T true PT3789389T (pt) | 2025-12-17 |
Family
ID=68386284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197971435T PT3789389T (pt) | 2018-05-02 | 2019-04-30 | Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11396518B2 (https=) |
| EP (5) | EP3789389B1 (https=) |
| JP (5) | JP2021523935A (https=) |
| KR (4) | KR102839924B1 (https=) |
| CN (7) | CN116813637A (https=) |
| AU (4) | AU2019263865B2 (https=) |
| BR (4) | BR112020021976A2 (https=) |
| CA (4) | CA3213055A1 (https=) |
| DK (1) | DK3789389T3 (https=) |
| ES (1) | ES3047059T3 (https=) |
| FI (1) | FI3789389T3 (https=) |
| PL (1) | PL3789389T3 (https=) |
| PT (1) | PT3789389T (https=) |
| WO (4) | WO2019210864A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116813637A (zh) | 2018-05-02 | 2023-09-29 | 天津合美医药科技有限公司 | 噻吩衍生物的晶型 |
| WO2025103428A1 (zh) * | 2023-11-14 | 2025-05-22 | 赣州和美药业股份有限公司 | 中重度斑块型银屑病的治疗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| AU2003243153A1 (en) * | 2002-04-23 | 2003-11-10 | Dr. Reddy's Laboratories Limited | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof |
| CN101186612B (zh) * | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
| BRPI1012770B8 (pt) | 2009-05-14 | 2021-05-25 | Tianjin Hemay Bio Tech Co Ltd | derivados de tiofeno |
| WO2012000499A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
| WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| IL297649A (en) | 2014-07-18 | 2022-12-01 | Green Cross Corp | Crystalline form of 5-chloro-m ({5)-2-oxo-3-[4-(6,5-dihydro-4-[1,2,4]triazin-1yl)phenyl}-1,3- Oxazolidine-5-yl} methyl) thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it |
| EP3144393A1 (en) * | 2015-09-18 | 2017-03-22 | LEK Pharmaceuticals d.d. | A synthetic pathway towards apremilast |
| CN107417626B (zh) * | 2016-05-23 | 2020-01-24 | 江苏奥赛康药业有限公司 | 一种2-氨基嘧啶类化合物的多晶型形式 |
| CN107474057B (zh) * | 2016-06-07 | 2021-03-12 | 天津药物研究院有限公司 | (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途 |
| US10570147B2 (en) | 2017-06-13 | 2020-02-25 | Biotheryx, Inc. | Bicyclic compounds and methods of use |
| ES2979170T3 (es) * | 2017-06-30 | 2024-09-24 | Trophy | Aparato de formación de imágenes dentales extraorales con detección de accesorios para el posicionamiento del paciente |
| CN116813637A (zh) * | 2018-05-02 | 2023-09-29 | 天津合美医药科技有限公司 | 噻吩衍生物的晶型 |
-
2019
- 2019-04-30 CN CN202310651520.8A patent/CN116813637A/zh not_active Withdrawn
- 2019-04-30 KR KR1020207034757A patent/KR102839924B1/ko active Active
- 2019-04-30 BR BR112020021976-2A patent/BR112020021976A2/pt unknown
- 2019-04-30 BR BR112020021945-2A patent/BR112020021945A2/pt active Search and Examination
- 2019-04-30 PT PT197971435T patent/PT3789389T/pt unknown
- 2019-04-30 US US17/052,077 patent/US11396518B2/en active Active
- 2019-04-30 FI FIEP19797143.5T patent/FI3789389T3/fi active
- 2019-04-30 AU AU2019263865A patent/AU2019263865B2/en active Active
- 2019-04-30 KR KR1020207034790A patent/KR20210022557A/ko not_active Ceased
- 2019-04-30 ES ES19797143T patent/ES3047059T3/es active Active
- 2019-04-30 AU AU2019262282A patent/AU2019262282B2/en active Active
- 2019-04-30 DK DK19797143.5T patent/DK3789389T3/da active
- 2019-04-30 US US17/052,128 patent/US12227514B2/en active Active
- 2019-04-30 US US17/052,131 patent/US12180222B2/en active Active
- 2019-04-30 JP JP2021510510A patent/JP2021523935A/ja active Pending
- 2019-04-30 CA CA3213055A patent/CA3213055A1/en active Pending
- 2019-04-30 CN CN202310701814.7A patent/CN116836178A/zh active Pending
- 2019-04-30 CN CN201910364512.9A patent/CN110437250B/zh active Active
- 2019-04-30 AU AU2019262284A patent/AU2019262284A1/en not_active Abandoned
- 2019-04-30 CN CN201910365332.2A patent/CN110437251B/zh active Active
- 2019-04-30 WO PCT/CN2019/085327 patent/WO2019210864A1/zh not_active Ceased
- 2019-04-30 WO PCT/CN2019/085360 patent/WO2019210869A1/zh not_active Ceased
- 2019-04-30 PL PL19797143.5T patent/PL3789389T3/pl unknown
- 2019-04-30 CA CA3098931A patent/CA3098931C/en active Active
- 2019-04-30 AU AU2019262286A patent/AU2019262286B2/en active Active
- 2019-04-30 CN CN202310657955.3A patent/CN116947878A/zh active Pending
- 2019-04-30 EP EP19797143.5A patent/EP3789389B1/en active Active
- 2019-04-30 EP EP19796979.3A patent/EP3800190A4/en not_active Withdrawn
- 2019-04-30 CN CN201910364369.3A patent/CN110437249B/zh active Active
- 2019-04-30 EP EP19795994.3A patent/EP3789387B1/en active Active
- 2019-04-30 KR KR1020207033658A patent/KR102686835B1/ko active Active
- 2019-04-30 JP JP2021510509A patent/JP7542523B2/ja active Active
- 2019-04-30 WO PCT/CN2019/085352 patent/WO2019210867A1/zh not_active Ceased
- 2019-04-30 CA CA3098927A patent/CA3098927C/en active Active
- 2019-04-30 BR BR112020022186-4A patent/BR112020022186A2/pt not_active Application Discontinuation
- 2019-04-30 CN CN202310699133.1A patent/CN116854705A/zh active Pending
- 2019-04-30 BR BR112020022190-2A patent/BR112020022190A2/pt active Search and Examination
- 2019-04-30 CA CA3099072A patent/CA3099072A1/en not_active Abandoned
- 2019-04-30 US US17/052,025 patent/US11274104B2/en active Active
- 2019-04-30 WO PCT/CN2019/085342 patent/WO2019210865A1/zh not_active Ceased
- 2019-04-30 JP JP2020561687A patent/JP7481263B2/ja active Active
- 2019-04-30 EP EP24152184.8A patent/EP4335515A3/en not_active Withdrawn
- 2019-04-30 JP JP2020561683A patent/JP7477459B2/ja active Active
- 2019-04-30 KR KR1020207033791A patent/KR102701245B1/ko active Active
- 2019-04-30 EP EP19796726.8A patent/EP3789388B1/en active Active
-
2023
- 2023-12-01 JP JP2023204100A patent/JP2024026251A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279468A (en) | Crystallographic modifications of odeviccibat | |
| IL271028A (en) | Inhibition of crystal growth of roflumilest | |
| IL272888B1 (en) | Uses of piperidinyl-indole derivatives | |
| HUE068568T2 (hu) | Új heterociklusos származékok, amelyek SHP2 inhibitorként hasznosíthatóak | |
| HUE065045T2 (hu) | Lanifibranor deuterált származékai | |
| SG11202106378VA (en) | Modulators of hsd17b13 expression | |
| SG11202102636UA (en) | Modulators of pnpla3 expression | |
| IL276592A (en) | History of Subtirum | |
| IL272697A (en) | A polymorphic form of TG02 | |
| IL273237A (en) | Novel heterocyclic compounds as MGLUR7 modulators | |
| PT3636640T (pt) | Cristal de derivado de acetamida de heterociclideno | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| PT3789389T (pt) | Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida | |
| PT3395819T (pt) | Forma cristalina de derivado de aminopirano substituído | |
| ZA202100484B (en) | Crystal of benzoxazole derivative | |
| SG11202105136WA (en) | Application of chidamide | |
| GB201807418D0 (en) | Improvements to open display refridgerators | |
| GB201807417D0 (en) | Improvements to open display refridgerators | |
| PT3901141T (pt) | Nova forma de isoquinolinossulfonamida | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| GB201721858D0 (en) | Update | |
| GB201714440D0 (en) | By contract of employment |